Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: A prospective randomized trial of the Italian oncology group for clinical research

G. Cocconi, G. Bisagni, M. Bacchi, C. Boni, R. Bartolucci, G. Ceci, M. A. Colozza, V. De Lisi, R. Lottici, A. M. Mosconi, R. Passalacqua, M. Tonato

Research output: Contribution to journalArticle

Abstract

In this prospective randomized study, first-line treatment with the combination of cisplatin (P) and etoposide (E) was compared with the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in 140 patients. Complete remissions were obtained in 11% of 65 assessable patients on CMF and in 12% of 65 assessable patients on PE. Complete plus partial remission rates were 48% on CMF and 63% on PE (P = .08). Time to progression (median, 32 v 31 weeks), duration of response (48 v 39 weeks), and survival (75 v 76 weeks) were not different. Hematologic toxicity was significantly higher with PE, and gastrointestinal side effects were frequent with this treatment. This study demonstrated that the PE combination is effective as front-line chemotherapy. As far as response rate is concerned, a trend of superiority over CMF was observed, which was of borderline significance. Due to the lack of survival advantage and to toxicity, this combination is not recommended for routine clinical use. However, its high level of activity should be taken into account for further research.

Original languageEnglish
Pages (from-to)664-669
Number of pages6
JournalJournal of Clinical Oncology
Volume9
Issue number4
Publication statusPublished - 1991

Fingerprint

Medical Oncology
Etoposide
Methotrexate
Fluorouracil
Cyclophosphamide
Cisplatin
Breast Neoplasms
Drug Therapy
Research
Survival
Prospective Studies
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma : A prospective randomized trial of the Italian oncology group for clinical research. / Cocconi, G.; Bisagni, G.; Bacchi, M.; Boni, C.; Bartolucci, R.; Ceci, G.; Colozza, M. A.; De Lisi, V.; Lottici, R.; Mosconi, A. M.; Passalacqua, R.; Tonato, M.

In: Journal of Clinical Oncology, Vol. 9, No. 4, 1991, p. 664-669.

Research output: Contribution to journalArticle

Cocconi, G, Bisagni, G, Bacchi, M, Boni, C, Bartolucci, R, Ceci, G, Colozza, MA, De Lisi, V, Lottici, R, Mosconi, AM, Passalacqua, R & Tonato, M 1991, 'Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: A prospective randomized trial of the Italian oncology group for clinical research', Journal of Clinical Oncology, vol. 9, no. 4, pp. 664-669.
Cocconi, G. ; Bisagni, G. ; Bacchi, M. ; Boni, C. ; Bartolucci, R. ; Ceci, G. ; Colozza, M. A. ; De Lisi, V. ; Lottici, R. ; Mosconi, A. M. ; Passalacqua, R. ; Tonato, M. / Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma : A prospective randomized trial of the Italian oncology group for clinical research. In: Journal of Clinical Oncology. 1991 ; Vol. 9, No. 4. pp. 664-669.
@article{74893f817f4d4200bbf03ef77973d722,
title = "Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: A prospective randomized trial of the Italian oncology group for clinical research",
abstract = "In this prospective randomized study, first-line treatment with the combination of cisplatin (P) and etoposide (E) was compared with the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in 140 patients. Complete remissions were obtained in 11{\%} of 65 assessable patients on CMF and in 12{\%} of 65 assessable patients on PE. Complete plus partial remission rates were 48{\%} on CMF and 63{\%} on PE (P = .08). Time to progression (median, 32 v 31 weeks), duration of response (48 v 39 weeks), and survival (75 v 76 weeks) were not different. Hematologic toxicity was significantly higher with PE, and gastrointestinal side effects were frequent with this treatment. This study demonstrated that the PE combination is effective as front-line chemotherapy. As far as response rate is concerned, a trend of superiority over CMF was observed, which was of borderline significance. Due to the lack of survival advantage and to toxicity, this combination is not recommended for routine clinical use. However, its high level of activity should be taken into account for further research.",
author = "G. Cocconi and G. Bisagni and M. Bacchi and C. Boni and R. Bartolucci and G. Ceci and Colozza, {M. A.} and {De Lisi}, V. and R. Lottici and Mosconi, {A. M.} and R. Passalacqua and M. Tonato",
year = "1991",
language = "English",
volume = "9",
pages = "664--669",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma

T2 - A prospective randomized trial of the Italian oncology group for clinical research

AU - Cocconi, G.

AU - Bisagni, G.

AU - Bacchi, M.

AU - Boni, C.

AU - Bartolucci, R.

AU - Ceci, G.

AU - Colozza, M. A.

AU - De Lisi, V.

AU - Lottici, R.

AU - Mosconi, A. M.

AU - Passalacqua, R.

AU - Tonato, M.

PY - 1991

Y1 - 1991

N2 - In this prospective randomized study, first-line treatment with the combination of cisplatin (P) and etoposide (E) was compared with the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in 140 patients. Complete remissions were obtained in 11% of 65 assessable patients on CMF and in 12% of 65 assessable patients on PE. Complete plus partial remission rates were 48% on CMF and 63% on PE (P = .08). Time to progression (median, 32 v 31 weeks), duration of response (48 v 39 weeks), and survival (75 v 76 weeks) were not different. Hematologic toxicity was significantly higher with PE, and gastrointestinal side effects were frequent with this treatment. This study demonstrated that the PE combination is effective as front-line chemotherapy. As far as response rate is concerned, a trend of superiority over CMF was observed, which was of borderline significance. Due to the lack of survival advantage and to toxicity, this combination is not recommended for routine clinical use. However, its high level of activity should be taken into account for further research.

AB - In this prospective randomized study, first-line treatment with the combination of cisplatin (P) and etoposide (E) was compared with the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in 140 patients. Complete remissions were obtained in 11% of 65 assessable patients on CMF and in 12% of 65 assessable patients on PE. Complete plus partial remission rates were 48% on CMF and 63% on PE (P = .08). Time to progression (median, 32 v 31 weeks), duration of response (48 v 39 weeks), and survival (75 v 76 weeks) were not different. Hematologic toxicity was significantly higher with PE, and gastrointestinal side effects were frequent with this treatment. This study demonstrated that the PE combination is effective as front-line chemotherapy. As far as response rate is concerned, a trend of superiority over CMF was observed, which was of borderline significance. Due to the lack of survival advantage and to toxicity, this combination is not recommended for routine clinical use. However, its high level of activity should be taken into account for further research.

UR - http://www.scopus.com/inward/record.url?scp=0026087138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026087138&partnerID=8YFLogxK

M3 - Article

C2 - 2066763

AN - SCOPUS:0026087138

VL - 9

SP - 664

EP - 669

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -